Achievements:
The most important achievement of her current research activity is that her scientific results underlie the start up of the first clinical trials (second semester of 2019) of a selective p110δ inhibitor for the treatment of breast cancer by a pharmaceutical company in Switzerland with which Dr Papakonstanti has developed a scientific collaboration.

Research Group:
Cell signalling in cancer & metastasis.

Current target signalling pathways:
PI3-kinase isoform specific- and Rho GTPases- regulated pathways in tumour growth and cancer cells migration.